Human Immunodeficiency Virus Therapeutics Market Size Expansion: Projected to Hit $18.57 Billion by 2029 with 5.6% Growth
The Business Research Company’s report on the Human Immunodeficiency Virus Therapeutics Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the primary drivers fueling the growth of the human immunodeficiency virus therapeutics market in recent years?
The growing prevalence of unprotected sexual practices is expected to propel the growth of the human immunodeficiency virus therapeutics market going forward. Unprotected sexual practices refer to sexual activities without barrier protection, increasing the risk of sexually transmitted infections (STIs) and unintended pregnancies. Lack of comprehensive sex education leads to limited awareness about safe practices, which increases risky behavior among youth. Human immunodeficiency virus therapeutics help reduce the risk of HIV transmission from unprotected sexual practices by suppressing viral load to undetectable levels, preventing further spread of the infection. For instance, in November 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, in a 2023 survey of U.S. high school students, 32% reported having had sexual intercourse at least once, and 48% stated that they did not use a condom during their most recent sexual encounter. Therefore, the growing prevalence of unprotected sexual practices is driving the growth of the human immunodeficiency virus therapeutics market.
Access Your Free Sample of the Global Human Immunodeficiency Virus Therapeutics Market Report — Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=23419&type=smp
What is the projected market size of the human immunodeficiency virus therapeutics industry, and how is it expected to grow?
The human immunodeficiency virus therapeutics market size has grown strongly in recent years. It will grow from $14.11 billion in 2024 to $14.94 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to rise in HIV prevalence, growth in awareness programs, rise in diagnostic testing, growth in generic drug penetration, and rise in healthcare infrastructure.
The human immunodeficiency virus therapeutics market size is expected to see strong growth in the next few years. It will grow to $18.57 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to rising HIV patient pool, increasing HIV screening, increase in voluntary testing, surge in unprotected sex practices, and expansion of government programs. Major trends in the forecast period include technological advancements, AI-driven drug discovery, long-acting injectable therapies, telemedicine integration, and CRISPR-based gene therapy.
Gain Exclusive Market Insights — Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=23419&type=smp
Who are the key players driving competition in the human immunodeficiency virus therapeutics market?
Major companies operating in the human immunodeficiency virus therapeutics market are Pfizer Inc., Johnson & Johnson, F Hoffmann La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol Myers Squibb Company (BMS), Novartis International AG, GlaxoSmithKline plc (GSK), Gilead Sciences Inc., Moderna Inc., BioNTech SE, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Aurobindo Pharma Limited, Cipla Limited, Hetero Labs Limited, Gilead Sciences Inc. / Kite Pharma Inc. (for CAR T HIV cure research), Vir Biotechnology Inc., Theratechnologies Inc., CytoDyn Inc.
Which emerging trends are set to transform the human immunodeficiency virus therapeutics market landscape?
Major companies operating in the human immunodeficiency virus (HIV) therapeutics market are focusing on developing innovative treatments, such as combination therapy, to improve treatment efficacy, reduce drug resistance, and enhance patient adherence. Combination therapy involves the use of two or more therapeutic agents, including drugs or other treatments, to manage a single disease or condition. This approach enhances treatment effectiveness, minimizes side effects, and lowers the risk of drug resistance. For instance, in December 2022, Gilead Sciences Inc., a US-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Sunlenca (lenacapavir). This treatment, used in combination with other antiretroviral medications, is designed for adults with multi-drug-resistant HIV-1. Sunlenca is notable for being the first and only HIV treatment based on a capsid inhibitor, offering a dosing option of twice a year for patients who have undergone extensive treatment. The approval is supported by the CAPELLA trial, which showed high rates of sustained virologic suppression. With its innovative mechanism of action and long-acting formulation, Sunlenca is anticipated to play a key role in future HIV treatment and prevention strategies.
Which key geographies are driving the growth of the human immunodeficiency virus therapeutics market?
North America was the largest region in the human immunodeficiency virus therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human immunodeficiency virus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/human-immunodeficiency-virus-therapeutics-global-market-report
What are the key segments driving growth in the human immunodeficiency virus therapeutics market?
The human immunodeficiency virus therapeutics market covered in this report is segmented –
1) By Drug Type: Branded Drugs, Generic Drugs
2) By Drug Class: Nucleoside-Analog Reverse Transcriptase Inhibitors (Nrtis), Non-Nucleoside Reverse Transcriptase Inhibitors (Nnrtis), Entry And Fusion Inhibitors, Protease Inhibitors (Pis), Integrase Inhibitors, Coreceptor Antagonists
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
4) By End-user: Hospitals And Clinics, Specialty Centers
Subsegments:
1) By Branded Drugs: Biktarvy, Triumeq, Genvoya, Juluca, Dovato, Isentress, Prezista
2) By Generic Drugs: Tenofovir Disoproxil Fumarate (TDF), Lamivudine, Efavirenz, Zidovudine, Nevirapine, Abacavir, Ritonavir
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23419
How is the human immunodeficiency virus therapeutics market defined, and what are its core characteristics?
Human immunodeficiency virus (HIV) therapeutics refer to medications and treatment strategies designed to manage and suppress HIV infection, primarily through antiretroviral therapy (ART). These therapeutics help reduce viral load, prevent disease progression to AIDS, and improve the quality of life for individuals living with HIV.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment